A part of Watch Media

MedWatchWednesday4 October 2023

Latest
Search
Log in

Pharma & biotech
Medtech
Hearing health
Regulation
Other

Search
Log in

MedWatchWednesday4 October 2023

Search
Log in

Pharma & biotech
Medtech
Hearing health
Regulation
Other

Top news from MedWatch this week

News about EMA, Novo Nordisk, Demant, Lundbeck, Coloplast, GN Group, and Boehringer Ingelheim.

Photo: MedWatch

by MIKKEL AABENHUS HEMMINGSEN

Monday

Former EMA deputy director has died

Novo Nordisk ramps up lobbying efforts for US obesity drug reimbursement

Tuesday

Analyst expects Demant to remain in high gear

Lundbeck’s key products under the microscope in CEO’s upcoming and last financial report

Wednesday

Demant’s growth continues to surge – operations disappoint slightly

Hearing aid market has finally fully normalized, says Demant CEO

Lundbeck upgrades after 13% sales growth in first half year

Thursday

Proud Deborah Dunsire passes the baton – but one decision she still has doubts about

Coloplast CEO: No more acquisitions here and now

GN scales back divestment efforts after improving cash flow

Friday

GN Hearing has cut 100 jobs

Boehringer Ingelheim plans phase III studies with obesity candidate from Zealand Pharma

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

E-mail address

Newsletter terms

Front page now

Foto: Staff/Reuters/Ritzau Scanpix

Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
FDA approves Novo Nordisk drug to treat rare condition

Foto: Mike Blake

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers

Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers

Foto: Novo Nordisk / Pr

Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers

Foto: Stine Bidstrup

Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers

Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom
The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.
For subscribers
FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.
For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.
For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.
For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.
Olympus appoints new chief medical officer
The new medical director is brought in from Medtronic.
For subscribers

Further reading

Foto: Mike Blake

Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers

Novo Nordisk's manufacturing facility in Clayton, the US. | Foto: Novo Nordisk/pr

Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers

Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr

Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers

Foto: Alexander Heinl/AP/Ritzau Scanpix

Pharma & biotech

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics

Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.

For subscribers

Foto: Staff

Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers

Foto: Tom Little

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Jobs

VP of Software Development, Perfusion Tech
Senior Analytical Scientists
Scientist - Bioanalysis, Biologics
Director, Head of Antibody Technology
Clinical Supply Manager
Senior QA Specialists (GMP or GCP)
Qualified Person to AJ Vaccines
Chemist for Incoming Materials in QC department
Senior Legal Councel
Clinical Trial Manager
QA/RA Manager
Audit & Supplier Manager
Supply Value Stream (SVS) Project Manager
Project Director, HR & ESG
Global Medical Manager
Discovery Project Leader, Principal Scientist
Senior CMC Specialist, Upstream Processing, Genmab

Latest news

Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
Pharmaceutical industry to grow 4% annually towards 2030 –
Zealand Pharma CEO: "We've never been stronger" –
Eli Lilly's head of diabetes and obesity retires –
DNB expects ALK's tablet sales to recover in 2024 –
Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
Olympus appoints new chief medical officer –
Low share price may knock Galecto off the stock exchange –

Jobs

VP of Software Development, Perfusion Tech
Senior Analytical Scientists
Scientist - Bioanalysis, Biologics
Director, Head of Antibody Technology
Clinical Supply Manager
Senior QA Specialists (GMP or GCP)
Qualified Person to AJ Vaccines
Chemist for Incoming Materials in QC department
Senior Legal Councel
Clinical Trial Manager
QA/RA Manager
Audit & Supplier Manager
Supply Value Stream (SVS) Project Manager
Project Director, HR & ESG
Global Medical Manager
Discovery Project Leader, Principal Scientist
Senior CMC Specialist, Upstream Processing, Genmab

Colophon

Sections

Pharma & biotech
Medtech
Hearing health
Regulation
Other
Sitemap
RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

Privacy Policy

Copyright © MedWatch — All rights reserved